Cargando…
晚期ALK融合阳性非小细胞肺癌治疗全程管理1例
BACKGROUND AND OBJECTIVE: Anaplastic lymphoma kinase (ALK) is an important therapeutic target for advanced non-small cell lung cancer (NSCLC). In recent years, with the emergence of several ALK tyrosine kinase inhibitors (TKI), the overall survival (OS) of ALK fusion positive patients is gradually e...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8387652/ https://www.ncbi.nlm.nih.gov/pubmed/34344501 http://dx.doi.org/10.3779/j.issn.1009-3419.2021.101.32 |